The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology

被引：121

作者：

Zauli, Giorgio

Secchiero, Paola

机构：

[1] Univ Trieste, Inst Normal Human Morphol, I-34138 Trieste, Italy

[2] Univ Ferrara, Dept Morphol & Embryol, I-44100 Ferrara, Italy

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2006年 / 17卷 / 04期

关键词：

TRAIL; hematopoiesis; endothelial cells; TRAIL receptors; OPG;

D O I：

10.1016/j.cytogfr.2006.04.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

TRAIL is a member of the tumor necrosis factor superfamily that interacts with an unusually complex receptor system, comprising transmembrane (TRAIL-R1, -R2, -R3 and -R4) and soluble (osteoprotegerin) receptors. TRAIL has received considerable attention because of the finding that many cancer cell types are sensitive to TRAIL-induced apoptosis. However, increasing experimental evidence shows that TRAIL exhibits regulatory roles in various normal tissues, as well. Although the best-characterized biological activity of TRAIL is in the homeostatic regulation of the immune system, in this review we have summarized and discussed the physiological function of TRAIL and its receptors, in normal hematopoiesis and vascular physiopathology. (c) 2006 Elsevier Ltd. All rights reserved.

引用

收藏

页码：245 / 257

页数：13

相关论文

共 137 条

[1] Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL [J].

Aktas, O ;

Smorodchenko, A ;

Brocke, S ;

Infante-Duarte, C ;

Topphoff, US ;

Vogt, J ;

Prozorovski, T ;

Meier, S ;

Osmanova, V ;

Pohl, E ;

Bechmann, I ;

Nitsch, R ;

Zipp, F .

NEURON, 2005, 46 (03) :421-432

[2]

ALLADINA SJ, 2005, J VASC RES

[3] Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].

Almasan, A ;

Ashkenazi, A .

CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348

[4] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[5] Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].

Ashkenazi, A .

NATURE REVIEWS CANCER, 2002, 2 (06) :420-430

[6] Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis [J].

Atkins, GJ ;

Bouralexis, S ;

Evdokiou, A ;

Hay, S ;

Labrinidis, A ;

Zannettino, ACW ;

Haynes, DR ;

Findlay, DM .

BONE, 2002, 31 (04) :448-456

[7] Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients [J].

Avignon, A ;

Sultan, A ;

Piot, C ;

Elaerts, S ;

Cristol, JP ;

Dupuy, AM .

DIABETES CARE, 2005, 28 (09) :2176-2180

[8] On the TRAIL to apoptosis [J].

Baetu, TM ;

Hiscott, J .

CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (03) :199-207

[9] Converging roads: Evidence for an adult hemangioblast [J].

Bailey, AS ;

Fleming, WH .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (11) :987-993

[10] Human NK cells lyse organ-specific endothelial cells: Analysis of adhesion and cytotoxic mechanisms [J].

Bielawska-Pohl, A ;

Crola, C ;

Caignard, A ;

Gaudin, C ;

Dus, D ;

Kieda, C ;

Chouaib, S .

JOURNAL OF IMMUNOLOGY, 2005, 174 (09) :5573-5582

← 1 2 3 4 5 6 7 8 9 10 →